BiotechTube

Trametinib

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurofibromatosis 1

Conditions

Neurofibromatosis 1, Child, Neurofibroma, Plexiform

Trial Timeline

Jun 10, 2019 → Dec 15, 2024

NCT ID
NCT03741101

About Trametinib

Trametinib is a phase 2 stage product being developed by Novartis for Neurofibromatosis 1. The current trial status is active. This product is registered under clinical trial identifier NCT03741101. Target conditions include Neurofibromatosis 1, Child, Neurofibroma, Plexiform.

What happened to similar drugs?

0 of 1 similar drugs in Neurofibromatosis 1 were approved

Approved (0) Terminated (0) Active (1)
🔄SelumetinibAstraZenecaPhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT03741101Phase 2Active
NCT03232892Phase 2Terminated
NCT02881242Phase 2Active

Competing Products

20 competing products in Neurofibromatosis 1

See all competitors
ProductCompanyStageHype Score
SelumetinibAstraZenecaPhase 2
27
SelumetinibAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1
29
AZD2014AstraZenecaPhase 2
35
Selumetinib + PlaceboAstraZenecaPhase 2
27
Treatment A + Treatment B + Treatment C + Treatment D + AcetaminophenAstraZenecaPhase 1
29
SelumetinibAstraZenecaPhase 1/2
32
SelumetinibAstraZenecaPhase 1
33
Selumetinib granule formulation + Selumetinib capsule formulationAstraZenecaPhase 1/2
36
SelumetinibAstraZenecaPhase 3
44
Everolimus (RAD001) , Afinitor®NovartisPhase 2
35
RAD001: EverolimusNovartisPhase 2
35
RAD001, everolimusNovartisPhase 2
27
TasignaNovartisPhase 1
29
Everolimus (RAD001)NovartisPhase 2
27
Sutent®/SunitinibPfizerPhase 2
27
Sorafenib (Nexavar)BayerPhase 2
24
PTC299United TherapeuticsPhase 2
24
REC-2282 + PlaceboRecursion PharmaceuticalsPhase 2/3
24
BinimetinibPacific BiosciencesPhase 2
25